breast cancer	is a	malignant neoplasm
breast cancer	arises in	breast tissue
breast cancer	includes subtype	invasive ductal carcinoma
breast cancer	includes subtype	invasive lobular carcinoma
breast cancer	overexpresses	HER2
breast cancer	is associated with	BRCA1 mutation
breast cancer	is associated with	BRCA2 mutation
breast cancer	has risk factor	age
breast cancer	has risk factor	family history
breast cancer	has risk factor	early menarche
breast cancer	has risk factor	late menopause
breast cancer	has risk factor	obesity
breast cancer	has risk factor	alcohol use
breast cancer	occurs in	females
breast cancer	detected by	mammography
mammography	detects	breast cancer
biopsy	confirms	breast cancer
biopsy	yields	tissue diagnosis
tissue diagnosis	shows	malignancy
breast cancer	staged by	TNM system
breast cancer	treated with	lumpectomy
breast cancer	treated with	mastectomy
breast cancer	treated with	chemotherapy
breast cancer	treated with	radiotherapy
breast cancer	treated with	endocrine therapy
breast cancer	treated with	targeted therapy
lumpectomy	followed by	radiation therapy
mastectomy	followed by	adjuvant therapy
chemotherapy	includes	alkylating agents
chemotherapy	includes	taxanes
endocrine therapy	includes	tamoxifen
endocrine therapy	includes	aromatase inhibitor
tamoxifen	blocks	estrogen receptor
aromatase inhibitor	lowers	estrogen
breast cancer	expresses	estrogen receptor
breast cancer	expresses	progesterone receptor
breast cancer	expresses	HER2 receptor
HER2 positive breast cancer	is a	subtype of breast cancer
triple-negative breast cancer	is a	molecular subtype
breast cancer	metastasizes to	bone
breast cancer	metastasizes to	liver
breast cancer	metastasizes to	lung
breast cancer	metastasizes to	brain
bone metastasis	causes	pain
bone metastasis	leads to	fracture
liver metastasis	causes	hepatic dysfunction
brain metastasis	causes	neurological deficits
breast cancer	worsens	survival
breast cancer	increases	mortality risk
breast cancer	associated with	lymphedema
breast cancer	associated with	fatigue
breast cancer	associated with	anemia
breast cancer	associated with	pain
breast cancer	monitored by	tumor markers
estrogen receptor status	guides	therapy selection
HER2 status	guides	targeted therapy suitability
lymph node involvement	influences	prognosis
tumor size	influences	treatment choice
breast cancer	increases	risk of contralateral cancer
contralateral breast cancer	occurs after	initial cancer
genetic testing	informs	family risk
BRCA1 mutation	indicates	hereditary breast cancer
BRCA2 mutation	indicates	hereditary breast cancer
environmental exposure	contributes to	breast cancer risk
obesity	increases	breast cancer risk
alcohol consumption	increases	breast cancer risk
late menopause	increases	breast cancer risk
early menarche	increases	breast cancer risk
pregnancy after age 30	increases	breast cancer risk
physical activity	reduces	breast cancer risk
breastfeeding	reduces	breast cancer risk
hormone replacement therapy	increases	breast cancer risk
tamoxifen	reduces	recurrence risk
aromatase inhibitor	reduces	estrogen levels
neoadjuvant therapy	reduces	tumor size
pathologic complete response	indicates	favorable prognosis
ER-positive breast cancer	responds to	endocrine therapy
HER2-positive breast cancer	responds to	HER2-targeted therapy
BRCA-mutated breast cancer	responds to	PARP inhibitors
resection margins	determine	recurrence risk
radiation therapy	reduces	local recurrence
neoadjuvant chemotherapy	allows	breast-conserving surgery
breast-conserving surgery	requires	clear margins
clear margins	predict	reduced recurrence
CA 15-3	is a	tumor marker
CA 15-3	used for	monitoring
bone scan	used for	metastasis evaluation
PET-CT	used for	staging
MRI	used for	breast cancer staging
ductal carcinoma in situ	is a	noninvasive form
invasive ductal carcinoma	is a	primary histology
DCIS	is a	noninvasive form
invasive lobular carcinoma	is a	histologic subtype
breast cancer prognosis depends on	stage
female patients	at risk for	breast cancer
premenopausal status	influences	treatment choice
postmenopausal status	influences	treatment choice
tumor grade	influences	prognosis
lymph node status	influences	surgical decisions
neoadjuvant chemotherapy	increases	breast-conserving eligibility
breast cancer	requires	multidisciplinary care
care team	coordinates	treatment plan
